Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7136205 | 0.87 | MEN1 (0.46) | FLT3MEN1KMT2ARPS6KA3NTRK1 | |
| SCHEMBL5366450 | 0.86 | FLT3 (0.50) | FLT3MEN1KMT2ARPS6KA3MDM2 | |
| SCHEMBL7134255 | 0.84 | FLT3 (0.54) | FLT3MEN1KMT2ARPS6KA3MDM2 | |
| SCHEMBL5364290 | 0.84 | MEN1 (0.44) | FLT3MEN1KMT2ARPS6KA3NTRK1 | |
| SCHEMBL5365701 | 0.81 | FLT3 (0.42) | FLT3MEN1KMT2ARPS6KA3MDM2 | |
| SCHEMBL5361178 | 0.80 | NTRK1 (0.41) | FLT3MEN1KMT2ARPS6KA3NTRK1 | |
| SCHEMBL7136594 | 0.79 | NPC1 (0.62) | FLT3MEN1KMT2ARPS6KA3NTRK1 | |
| SCHEMBL7133366 | 0.78 | NTRK1 (0.53) | NTRK1KDRPDPK1 | |
| SCHEMBL7139535 | 0.78 | LRRK2 (0.49) | FLT3MEN1KMT2ARPS6KA3NTRK1 | |
| SCHEMBL14674037 | 0.77 | MEN1 (0.69) | FLT3MEN1KMT2ARPS6KA3MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | FLT3 395/4885MEN1 3855/4885KMT2A 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.